• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    9/6/22 1:43:02 PM ET
    $ALNA
    $EIGR
    $FWBI
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALNA alert in real time by email

     

    Gainers

    • Spero Therapeutics (NASDAQ:SPRO) shares increased by 134.6% to $1.71 during Tuesday's regular session. Spero Therapeutics's stock is trading at a volume of 34.7 million shares as of 13:31 EST. This is 12229.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $59.7 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 71.43% to $25.54. Trading volume for Shuttle Pharmaceuticals's stock is 11.3 million as of 13:31 EST. This is 577.6% of its average full-day volume over the last 100 days. The company's market cap stands at $339.3 million.
    • IVERIC bio (NASDAQ:ISEE) stock increased by 56.67% to $14.79. As of 13:31 EST, IVERIC bio's stock is trading at a volume of 100.3 million, which is 4792.5% of its average full-day volume over the last 100 days. The company's market cap stands at $1.7 billion.
    • First Wave BioPharma (NASDAQ:FWBI) stock increased by 42.76% to $4.54. The current volume of 23.5 million shares is 12445.9% of First Wave BioPharma's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $6.2 million.
    • Nutex Health (NASDAQ:NUTX) stock rose 27.61% to $3.05. The current volume of 10.3 million shares is 812.7% of Nutex Health's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $1.9 billion.
    • Galera Therapeutics (NASDAQ:GRTX) shares increased by 20.26% to $1.55. As of 13:31 EST, Galera Therapeutics's stock is trading at a volume of 259.2K, which is 350.6% of its average full-day volume over the last 100 days. The company's market cap stands at $41.6 million.

    Losers

    • Allena Pharma (NASDAQ:ALNA) stock fell 42.7% to $0.06 during Tuesday's regular session. As of 13:31 EST, this security is trading at a volume of 37.8 million shares, making up 146.6% of its average full-day volume over the last 100 days. The company's market cap stands at $7.3 million.
    • POINT Biopharma Global (NASDAQ:PNT) shares fell 32.05% to $6.96. As of 13:31 EST, this security is trading at a volume of 1.9 million shares, making up 284.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $627.1 million.
    • ProKidney (NASDAQ:PROK) shares decreased by 30.5% to $7.09. ProKidney's stock is trading at a volume of 147.6K shares as of 13:31 EST. This is 284.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $436.3 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) stock decreased by 30.12% to $5.97. The current volume of 886.4K shares is 283.2% of Eiger BioPharmaceuticals's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $262.7 million.
    • TherapeuticsMD (NASDAQ:TXMD) shares decreased by 20.93% to $8.05. The current volume of 192.4K shares is 23.0% of TherapeuticsMD's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $75.8 million.
    • bioAffinity Technologies (NASDAQ:BIAF) shares declined by 18.3% to $5.76. As of 13:31 EST, this security is trading at a volume of 1.7 million shares, making up 19.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNA
    $EIGR
    $FWBI
    $GRTX

    CompanyDatePrice TargetRatingAnalyst
    ProKidney Corp.
    $PROK
    12/16/2025$12.00Buy
    H.C. Wainwright
    ProKidney Corp.
    $PROK
    6/30/2025$1.00Neutral → Underperform
    BofA Securities
    Spero Therapeutics Inc.
    $SPRO
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    Nutex Health Inc.
    $NUTX
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    ProKidney Corp.
    $PROK
    9/30/2024Neutral
    JP Morgan
    Nutex Health Inc.
    $NUTX
    9/18/2024$45.00Buy
    Maxim Group
    ProKidney Corp.
    $PROK
    9/10/2024$6.00Buy
    Guggenheim
    ProKidney Corp.
    $PROK
    3/7/2024$3.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

    The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

    3/3/26 5:31:00 PM ET
    $AMGN
    $IRON
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IZERVAY issued to IVERIC BIO, INC.

    Submission status for IVERIC BIO, INC.'s drug IZERVAY (ORIG-1) with active ingredient AVACINCAPTAD PEGOL has changed to 'Approval' on 08/04/2023. Application Category: NDA, Application Number: 217225, Application Classification: Type 1 - New Molecular Entity

    8/9/23 8:37:19 AM ET
    $ISEE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

    11/17/21 4:38:32 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ProKidney Corp. with a new price target

    H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

    12/16/25 9:01:44 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Corp. downgraded by BofA Securities with a new price target

    BofA Securities downgraded ProKidney Corp. from Neutral to Underperform and set a new price target of $1.00

    6/30/25 7:57:01 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Spero Therapeutics downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Spero Therapeutics from Outperform to In-line and set a new price target of $5.00

    12/20/24 7:51:16 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    SEC Filings

    View All

    SEC Form S-8 filed by Nutex Health Inc.

    S-8 - Nutex Health Inc. (0001479681) (Filer)

    3/10/26 11:35:55 AM ET
    $NUTX
    Real Estate

    Nutex Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nutex Health Inc. (0001479681) (Filer)

    3/5/26 4:11:50 PM ET
    $NUTX
    Real Estate

    SEC Form 10-K filed by Nutex Health Inc.

    10-K - Nutex Health Inc. (0001479681) (Filer)

    3/5/26 4:10:58 PM ET
    $NUTX
    Real Estate

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Coulston James

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    3/3/26 7:59:02 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Regulatory Officer Weber Darin J.

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    3/3/26 7:58:38 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Legal Officer Girolamo Todd C

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    3/3/26 7:58:18 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    Large owner Control Empresarial De Capitales S.A. De C.V. bought $276,366 worth of Class A Ordinary Shares (387,393 units at $0.71) (SEC Form 4)

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    4/24/25 4:15:43 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    Leadership Updates

    Live Leadership Updates

    View All

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER

    HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments  in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Wesley Bamburg as the Company's Chief Operating Officer, effective October 13, 2025. Mr. Bamburg is an accomplished healthcare executive with 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Mr. Bamburg has served as Chief Operating Officer for HCA Houst

    9/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITOR

    HOUSTON, May 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to replace CBIZ CPAs ("CBIZ"), effective May 15, 2025. The change of the Company's independent auditor was made after careful consideration and an evaluation process and was approved by the Audit Committee and the Board of Directors of the

    5/22/25 6:30:00 AM ET
    $NUTX
    Real Estate

    Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

    CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

    4/28/25 4:01:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

    SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    11/14/24 5:37:55 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nutex Health Inc.

    SC 13G - Nutex Health, Inc. (0001479681) (Subject)

    11/14/24 11:02:17 AM ET
    $NUTX
    Real Estate

    SEC Form SC 13G filed by TherapeuticsMD Inc.

    SC 13G - TherapeuticsMD, Inc. (0000025743) (Subject)

    11/12/24 4:40:08 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $EIGR
    $FWBI
    $GRTX
    Financials

    Live finance-specific insights

    View All

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    NUTEX HEALTH REPORTS SEPTEMBER 30, 2025 THIRD QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS

    Total revenue of $723.6 million for the first nine months of 2025 versus $222.3 million for the first nine months of 2024, an increase of 225.5%Net income attributable to Nutex Health Inc. of $59.0 million for the first nine months of 2025 versus net loss of $9.5 million for the first nine months of 2024, an increase of $68.5 millionDiluted income per share of $8.87 for the first nine months of 2025 versus a loss per share of $1.91 for the first nine months of 2024EBITDA of $142.9 million for the first nine months of 2025 versus $19.9 million for the first nine months of 2024, an increase of 616.4%Adjusted EBITDA of $243.0 million for the first nine months of 2025 versus $16.1 million for th

    11/19/25 4:30:00 PM ET
    $NUTX
    Real Estate